Clearly, these studies underscore the need to analyze the role(s) of the AMPK isoforms in the response of breast cancer cells to all antiestrogen treatments, and to determine if selective blockade of AMPKα2 is a viable molecular approach to combat antiestrogen resistance and delay relapse. The gene discussed is PRKAA2; the disease is breast cancer.